Physician profile
Natalie Bellini
NPI 1619436664
$582,140.60
in general payments reported to CMS, 2019-2025
51 companies · $167K in 2025
The $167K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42K · 2022: $75K · 2023: $64K · 2024: $234K · 2025: $167K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $192K · Consulting Fee: $165K · Travel and Lodging: $74K · Food and Beverage: $20K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Education: $119 · Long Term Medical Supply Or Device Loan: $49.95 · Gift: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $191,500.23 |
| Consulting Fee | $165,325.00 |
| Travel and Lodging | $73,685.94 |
| Food and Beverage | $19,655.32 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,899.37 |
| Education | $119.47 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Gift | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $198,710.17 | 2021-2025 | |
| Abbott Laboratories | $181,409.26 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Embecta Corp. | $93,904.29 | 2023-2024 | |
| Sequel Med Tech, LLC | $32,885.40 | 2024-2025 | Twiist |
| Genzyme Corporation | $13,403.48 | 2025 | |
| Medtronic, INC. | $11,576.34 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Corcept Therapeutics | $11,033.70 | 2023-2025 | Korlym |
| Mannkind Corporation | $9,294.82 | 2021-2025 | Afrezza |
| Dexcom, INC. | $5,564.03 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $5,030.28 | 2023-2024 | |
| Lilly USA, LLC | $4,726.76 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Eli Lilly and Company | $3,750.00 | 2024-2025 | |
| Insulet Corporation | $2,604.56 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $2,232.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lifescan, INC. | $1,078.52 | 2022 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $840.21 | 2022-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.95 | 2021-2025 | Jardiance, Tradjenta |
| Xeris Pharmaceuticals, INC. | $548.31 | 2021-2025 | Gvoke Hypopen, Keveyis, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $309.60 | 2021-2025 | |
| Senseonics, Incorporated | $273.44 | 2022-2024 | Eversense |
| Amgen INC. | $246.74 | 2021-2022 | |
| Averitas Pharma INC. | $198.19 | 2023-2025 | Qutenza |
| Madrigal Pharmaceuticals | $183.10 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $160.82 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $155.82 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $147.24 | 2024-2025 | Crenessity |
| Abbvie INC. | $142.47 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $123.42 | 2021-2022 | |
| Kyowa Kirin, INC. | $92.67 | 2023-2025 | Crysvita |
| Pfizer INC. | $90.76 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $79.82 | 2021-2025 | Isturisa |
| Merck Sharp & Dohme LLC | $73.63 | 2021-2022 | |
| Beta Bionics, INC. | $72.44 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $62.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.28 | 2022-2025 | |
| Amphastar Pharmaceuticals, INC. | $44.76 | 2025 | |
| Zealand Pharma US, INC. | $38.60 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.98 | 2023-2025 | Shingrix, Arexvy |
| Horizon Therapeutics Plc | $30.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.48 | 2021-2022 | |
| Clarus Therapeutics INC. | $26.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $25.28 | 2025 | Strensiq |
| Daiichi Sankyo INC. | $23.92 | 2022 | |
| Eusa Pharma (US) LLC | $22.47 | 2022 | |
| Ibsa Pharma INC. | $19.65 | 2021 | |
| Amneal Pharmaceuticals LLC | $18.16 | 2025 | Unithroid |
| Acella Pharmaceuticals, LLC | $15.80 | 2024 | NP Thyroid 60 |
| Ascendis Pharma Endocrinology INC | $15.43 | 2025 | Yorvipath |
| Amryt Pharma Holdings Ltd | $14.69 | 2023 | Mycapssa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Bellini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.